A case of acquired Fanconi syndrome induced by zoledronic acid

Internal Medicine

Volumn 50, Issue 9, 2011, Pages 1075-1079

  Yoshinami, Tetsuhiro ^a   Yagi, Toshinari ^a   Sakai, Daisuke ^a   Sugimoto, Naotoshi ^a   Imamura, Fumio ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Fanconi syndrome; Metastatic breast cancer; Nephrotoxicity; Zoledronic acid

Indexed keywords

AMINO ACID; BETA 2 MICROGLOBULIN; BICARBONATE; CALCIUM; CREATININE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GLUCOSE; HEMOGLOBIN A1C; PACLITAXEL; PHOSPHATE; POTASSIUM; PROGESTERONE RECEPTOR; PROTEIN; SERUM ALBUMIN; SPIRONOLACTONE; TRASTUZUMAB; URIC ACID; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ALBUMIN BLOOD LEVEL; AMINO ACID ANALYSIS; AMINOACIDURIA; ANION GAP; ANOREXIA; ARTICLE; AXILLARY LYMPH NODE; BICARBONATE BLOOD LEVEL; BLOOD PH; BREAST CANCER; BREAST SURGERY; CALCIUM BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE SEQUENCE; DRUG INFUSION; ELECTROLYTE DISTURBANCE; FANCONI RENOTUBULAR SYNDROME; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; HYPERCHLOREMIC METABOLIC ACIDOSIS; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOURICEMIA; LIVER METASTASIS; LOADING DRUG DOSE; LYMPH NODE DISSECTION; MALIGNANCY ASSOCIATED HYPERCALCEMIA; METABOLIC ACIDOSIS; MULTIPLE CYCLE TREATMENT; PHOSPHATURIA; POTASSIUM EXCRETION; PROTEIN URINE LEVEL; PROTEINURIA; RENAL DIABETES; URIC ACID URINE LEVEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FANCONI SYNDROME; FEMALE; HUMANS; HYPERCALCEMIA; IMIDAZOLES; KIDNEY FUNCTION TESTS; MIDDLE AGED;

EID: 79955589449     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4855     Document Type: Article

References (16)

1. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Druginduced Fanconi's syndrome. Am J Kidney Dis 41: 292-309, 2003.
2. Kawada K, Minami H, Okabe K, et al. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 35: 28-33, 2005.
3. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate. Kidney Int 64: 281-289, 2003.
4. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 74: 1385-1393, 2008.
5. Pfister T, Atzpodien E, Bohrmann B, Bauss F. Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 97: 374-381, 2005.
6. The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer (the 16th edition). (in Japanese).
7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245, 1981.
8. Merouani A, Davidson SA, Schrier RW. Increased nephrotoxicity of combination Taxol and Cisplatin chemotherapy in gynecologic cancers as compared to Cisplatin alone. Am J Nephrol 17: 53-58, 1997.
9. Horm JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41: 674-680, 2007.
10. Major PP, Coleman RE. Zoledronic acid in treatment of hypercalcemia of malignancy: Results of the International Clinical Development Program. Semin Oncol 28 (Suppl 6): 17-24, 2001.
11. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind comparative trial. Cancer J 7: 377-387, 2001.
12. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastatic in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21: 3150-3157, 2003.
13. Rosen LS, Gordon D, Tchekmedyian S, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer 100: 2613-2621, 2004.
14. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 349: 1676-1679, 2003.
15. Buysschaert M, Cosyns JP, Barreto L, Ladoul M. Pamidronateinduced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant 18: 826-829, 2003.
16. Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 80: 225-230, 1997.